{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:22:24Z","timestamp":1790446944198,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Alterations in the renin\u2013angiotensin system have been implicated in the pathophysiology of septic shock. In particular, angiotensin 1\u20137 (Ang-(1\u20137)), an anti-inflammatory heptapeptide, has been hypothesized to have beneficial effects. The aim of the present study was to test the effects of Ang-(1\u20137) infusion on the development and severity of septic shock.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This randomized, open-label, controlled study was performed in 14 anesthetized and mechanically ventilated sheep. Immediately after sepsis induction by bacterial peritonitis, animals received either Ang-(1\u20137) (<jats:italic>n<\/jats:italic>\u2009=\u20097) or placebo (<jats:italic>n<\/jats:italic>\u2009=\u20097) intravenously. Fluid resuscitation, antimicrobial therapy, and peritoneal lavage were initiated 4\u00a0h after sepsis induction. Norepinephrine administration was titrated to maintain mean arterial pressure (MAP) between 65 and 75\u00a0mmHg.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were no differences in baseline characteristics between groups. Septic shock was prevented in 6 of the 7 animals in the Ang-(1\u20137) group at the end of the 24-h period. Fluid balance and MAP were similar in the two groups; however, MAP was achieved with a mean norepinephrine dose of 0.4\u00a0\u03bcg\/kg\/min in the Ang-(1\u20137) group compared to 4.3\u00a0\u03bcg\/kg\/min in the control group. Heart rate and cardiac output index were lower in the Ang (1\u20137) than in the control group, as were plasma interleukin-6 levels, and creatinine levels. Platelet count and PaO<jats:sub>2<\/jats:sub>\/FiO<jats:sub>2<\/jats:sub> ratio were higher in the Ang-(1\u20137) group. Mean arterial lactate at the end of the experiment was 1.6\u00a0mmol\/L in the Ang-(1\u20137) group compared to 7.4\u00a0mmol\/L in the control group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this experimental septic shock model, early Ang-(1\u20137) infusion prevented the development of septic shock, reduced norepinephrine requirements, limited interleukine-6 increase and prevented renal dysfunction.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13054-023-04396-8","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T13:03:48Z","timestamp":1678712628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Angiotensin 1\u20137 in an experimental septic shock model"],"prefix":"10.1186","volume":"27","author":[{"given":"Bruno","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Manicone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Dewachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Favory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Khaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Moiroux-Sahroui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Herpain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Creteur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Silvio","family":"Taccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Annoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"key":"4396_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801\u201310.","journal-title":"JAMA"},{"key":"4396_CR2","first-page":"1","volume":"2021","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock. Intensive Care Med. 2021;2021:1\u201367.","journal-title":"Intensive Care Med"},{"key":"4396_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study. Lancet. 2020;395:200\u201311.","journal-title":"Lancet"},{"key":"4396_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s00134-019-05544-x","volume":"45","author":"DD Backer","year":"2019","unstructured":"Backer DD, Cecconi M, Lipman J, Machado F, Myatra SN, Ostermann M, et al. Challenges in the management of septic shock: a narrative review. Intensive Care Med. 2019;45:420\u201333.","journal-title":"Intensive Care Med"},{"key":"4396_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13054-019-2478-6","volume":"23","author":"J-L Vincent","year":"2019","unstructured":"Vincent J-L, Jones G, David S, Olariu E, Cadwell KK. Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care. 2019;23:196.","journal-title":"Crit Care"},{"key":"4396_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13054-020-2733-x","volume":"24","author":"R Bellomo","year":"2020","unstructured":"Bellomo R, Wunderink RG, Szerlip H, English SW, Busse LW, Deane AM, et al. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Crit Care. 2020;24:43.","journal-title":"Crit Care"},{"key":"4396_CR7","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1164\/rccm.201911-2172OC","volume":"202","author":"R Bellomo","year":"2020","unstructured":"Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW, et al. Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial. Am J Respir Crit Care Med. 2020;202:1253\u201361.","journal-title":"Am J Respir Crit Care Med"},{"key":"4396_CR8","first-page":"526","volume":"203","author":"LS Chawla","year":"2020","unstructured":"Chawla LS, Bellomo R. Reply to: Alteration of the renin\u2013angiotensin-aldosterone system in shock: role of the dipeptidyl peptidase 3. Am J Respir Crit Care Med. 2020;203:526\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"4396_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13054-018-1995-z","volume":"22","author":"A Hall","year":"2018","unstructured":"Hall A, Busse LW, Ostermann M. Angiotensin in critical care. Crit Care. 2018;22:69.","journal-title":"Crit Care"},{"key":"4396_CR10","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13054-018-2202-y","volume":"22","author":"LS Chawla","year":"2018","unstructured":"Chawla LS, Chen S, Bellomo R, Tidmarsh GF. Angiotensin converting enzyme defects in shock: implications for future therapy. Crit Care. 2018;22:274.","journal-title":"Crit Care"},{"key":"4396_CR11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1164\/rccm.202010-3873LE","volume":"203","author":"A Picod","year":"2020","unstructured":"Picod A, Deniau B, Ayar PV, Genest M, Julian N, Azibani F, et al. Alteration of the renin\u2013angiotensin\u2013aldosterone system in shock: role of the dipeptidyl peptidase 3. Am J Respir Crit Care Med. 2020;203:526\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"4396_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJMoa1704154","volume":"377","author":"A Khanna","year":"2017","unstructured":"Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory shock. New Engl J Med. 2017;377:419\u201330.","journal-title":"New Engl J Med"},{"key":"4396_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112\u20136.","journal-title":"Nature"},{"key":"4396_CR14","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1161\/HYPERTENSIONAHA.113.01274","volume":"63","author":"RA Santos","year":"2014","unstructured":"Santos RA. Angiotensin-(1\u20137). Hypertension. 2014;63:1138\u201347.","journal-title":"Hypertension"},{"key":"4396_CR15","doi-asserted-by":"publisher","first-page":"601909","DOI":"10.3389\/fphar.2021.601909","volume":"12","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Xu D, Deng F, Yan Y, Li J, Zhang C, et al. Angiotensin (1\u20137) attenuates sepsis-induced acute kidney injury by regulating the NF-\u03baB pathway. Front Pharmacol. 2021;12:601909.","journal-title":"Front Pharmacol"},{"key":"4396_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40635-015-0044-3","volume":"3","author":"V Zambelli","year":"2015","unstructured":"Zambelli V, Bellani G, Borsa R, Pozzi F, Grassi A, Scanziani M, et al. Angiotensin-(1\u20137) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome. Intensive Care Med Exp. 2015;3:8.","journal-title":"Intensive Care Med Exp"},{"key":"4396_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13054-018-2210-y","volume":"22","author":"H-J Tsai","year":"2018","unstructured":"Tsai H-J, Liao M-H, Shih C-C, Ka S-M, Tsao C-M, Wu C-C. Angiotensin-(1\u20137) attenuates organ injury and mortality in rats with polymicrobial sepsis. Crit Care. 2018;22:269.","journal-title":"Crit Care"},{"key":"4396_CR18","first-page":"00114","volume":"7","author":"ALV Martins","year":"2021","unstructured":"Martins ALV, da Silva FA, Bolais-Ramos L, de Oliveira GC, Ribeiro RC, Pereira DAA, et al. Increased circulating levels of angiotensin-(1\u20137) in severely ill COVID-19 patients. ERJ Open Res. 2021;7:00114\u20132021.","journal-title":"ERJ Open Res"},{"key":"4396_CR19","doi-asserted-by":"crossref","first-page":"00848","DOI":"10.1183\/23120541.00848-2020","volume":"7","author":"D van Lier","year":"2021","unstructured":"van Lier D, Kox M, Santos K, van der Hoeven H, Pillay J, Pickkers P. Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients. ERJ Open Res. 2021;7:00848\u20132020.","journal-title":"ERJ Open Res"},{"key":"4396_CR20","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","volume":"18","author":"NP du Sert","year":"2020","unstructured":"du Sert NP, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18:e3000410.","journal-title":"PLoS Biol"},{"key":"4396_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/SHK.0000000000001212","volume":"50","author":"MF Osuchowski","year":"2018","unstructured":"Osuchowski MF, Ayala A, Bahrami S, Bauer M, Boros M, Cavaillon J-M, et al. Minimum quality threshold in pre-clinical sepsis studies (MQTiPSS). Shock. 2018;50:377\u201380.","journal-title":"Shock"},{"key":"4396_CR22","doi-asserted-by":"publisher","first-page":"R140","DOI":"10.1186\/cc9205","volume":"14","author":"FS Taccone","year":"2010","unstructured":"Taccone FS, Su F, Pierrakos C, He X, James S, Dewitte O, et al. Cerebral microcirculation is impaired during sepsis: an experimental study. Crit Care. 2010;14:R140.","journal-title":"Crit Care"},{"key":"4396_CR23","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1097\/CCM.0b013e3182a641b8","volume":"42","author":"FS Taccone","year":"2014","unstructured":"Taccone FS, Su F, Deyne CD, Abdellhai A, Pierrakos C, He X, et al. Sepsis is associated with altered cerebral microcirculation and tissue hypoxia in experimental peritonitis. Crit Care Med. 2014;42:e114\u201322.","journal-title":"Crit Care Med"},{"key":"4396_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/CCM.0000000000001380","volume":"44","author":"X He","year":"2016","unstructured":"He X, Su F, Taccone FS, Laporte R, Kj\u00f8lbye AL, Zhang J, et al. A selective V(1A) receptor agonist, selepressin, is superior to arginine vasopressin and to norepinephrine in ovine septic shock. Crit Care Med. 2016;44:23\u201331.","journal-title":"Crit Care Med"},{"key":"4396_CR25","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41598-020-79902-x","volume":"11","author":"H-J Tsai","year":"2021","unstructured":"Tsai H-J, Shih C-C, Chang K-Y, Liao M-H, Liaw W-J, Wu C-C, et al. Angiotensin-(1\u20137) treatment blocks lipopolysaccharide-induced organ damage, platelet dysfunction, and IL-6 and nitric oxide production in rats. Sci Rep. 2021;11:610.","journal-title":"Sci Rep"},{"key":"4396_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13054-022-04096-9","volume":"26","author":"G Wagener","year":"2022","unstructured":"Wagener G, Goldklang MP, Gerber A, Elisman K, Eiseman KA, Fonseca LD, et al. A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1\u20137 (TXA-127) for the treatment of severe COVID-19. Crit Care. 2022;26:229.","journal-title":"Crit Care"},{"key":"4396_CR27","doi-asserted-by":"crossref","unstructured":"Hollenberg SM, Singer M. Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol. 2021;1\u201311.","DOI":"10.1038\/s41569-020-00492-2"},{"key":"4396_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/ncpcardio1066","volume":"5","author":"AR Lyon","year":"2008","unstructured":"Lyon AR, Rees PS, Prasad S, Poole-Wilson PA, Harding SE. Stress (Takotsubo) cardiomyopathy\u2014a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Card. 2008;5:22\u20139.","journal-title":"Nat Clin Pract Card"},{"key":"4396_CR29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1161\/HYPERTENSIONAHA.115.05093","volume":"66","author":"J Wysocki","year":"2015","unstructured":"Wysocki J, Wilsbacher L, Batlle D. Angiotensins and the heart: is angiotensin-(1\u20137) cardioprotective? Hypertens. 2015;66:260\u20132.","journal-title":"Hypertens"},{"key":"4396_CR30","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","volume":"118","author":"VB Patel","year":"2016","unstructured":"Patel VB, Zhong J-C, Grant MB, Oudit GY. Role of the ACE2\/angiotensin 1\u20137 axis of the renin\u2013angiotensin system in heart failure. Circ Res. 2016;118:1313\u201326.","journal-title":"Circ Res"},{"key":"4396_CR31","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1164\/rccm.202012-4461OC","volume":"204","author":"L Gerard","year":"2021","unstructured":"Gerard L, Lecocq M, Bouzin C, Hoton D, Schmit G, Pereira JP, et al. Increased angiotensin-converting enzyme 2 and loss of alveolar type II cells in COVID-19\u2013related acute respiratory distress syndrome. Am J Respir Crit Care Med. 2021;204:1024\u201334.","journal-title":"Am J Respir Crit Care Med"},{"key":"4396_CR32","doi-asserted-by":"publisher","first-page":"104363","DOI":"10.1016\/j.ebiom.2022.104363","volume":"86","author":"WJ Wiersinga","year":"2022","unstructured":"Wiersinga WJ, van der Poll T. Immunopathophysiology of human sepsis. EBioMedicine. 2022;86:104363.","journal-title":"EBioMedicine"},{"key":"4396_CR33","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1164\/rccm.202002-0339OC","volume":"202","author":"R Stolk","year":"2020","unstructured":"Stolk R, van der Pasch E, Naumann F, Schouwstra J, Bressers S, van Herwaarden T, et al. Norepinephrine dysregulates the immune response and compromises host defense during sepsis. Am J Respir Crit Care Med. 2020;202:830\u201342.","journal-title":"Am J Respir Crit Care Med"},{"key":"4396_CR34","doi-asserted-by":"publisher","first-page":"e2211370119","DOI":"10.1073\/pnas.2211370119","volume":"119","author":"DE Leisman","year":"2022","unstructured":"Leisman DE, Privratsky JR, Lehman JR, Abraham MN, Yaipan OY, Brewer MR, et al. Angiotensin II enhances bacterial clearance via myeloid signaling in a murine sepsis model. Proc Natl Acad Sci. 2022;119:e2211370119.","journal-title":"Proc Natl Acad Sci"},{"key":"4396_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1164\/rccm.201801-0088CI","volume":"199","author":"J-L Teboul","year":"2019","unstructured":"Teboul J-L, Monnet X, Chemla D, Michard F. Arterial pulse pressure variation with mechanical ventilation. Am J Respir Crit Care Med. 2019;199:22\u201331.","journal-title":"Am J Respir Crit Care Med"},{"key":"4396_CR36","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1007\/s00134-013-2906-z","volume":"39","author":"AW Kirkpatrick","year":"2013","unstructured":"Kirkpatrick AW, Roberts DJ, Waele JD, Jaeschke R, Malbrain MLNG, et al. Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. Intensive Care Med. 2013;39:1190\u2013206.","journal-title":"Intensive Care Med"},{"key":"4396_CR37","first-page":"304","volume":"43","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;43:304\u201377.","journal-title":"Crit Care Med"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04396-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-023-04396-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04396-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T13:08:46Z","timestamp":1678712926000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-023-04396-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4396"],"URL":"https:\/\/doi.org\/10.1186\/s13054-023-04396-8","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"assertion":[{"value":"4 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local animal ethics committee (Comit\u00e9 Ethique du Bien-\u00catre Animal; protocol number 772N) from the Universit\u00e9 Libre de Bruxelles in Brussels (Belgium). Experiments were performed in the Experimental Laboratory of Intensive Care of the ULB (LA1230406).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}